SGLT2s are currently only approved for use in the U.S. for type 2 diabetes, but a lot of people with type 1 are taking them off label with positive results.
[read_more text="read more" title="read more" url="https://tcoyd.org/2019/07/a-dose-of-dr-e-fight-night-an-sglt-smackdown/" align="left"]
The newest classes of diabetes meds to treat type 2 are pulling more than double duty, helping to better control blood sugars, protect the heart, lower body weight and prevent chronic kidney disease.
[read_more text="read more" title="read more" url="https://tcoyd.org/2019/03/diabetes-medicines-that-help-your-waistline-and-your-heart/" align="left"]
SGLT-2 Inhibitors including Invokana (canagliflozin), Farxiga (dapagliflozin), Jardiance (empagliflozin) and Steglatro (ertugliflizin), are the newest class of oral medications for the treatment of type 2 diabetes. They’re generally well tolerated and associated with significant weight loss compared with other type 2 oral meds, but there are still precautions to consider.
[read_more text="read more" title="read more" url="https://tcoyd.org/2019/02/evaluating-type-2-meds-part-5-sglt-2-sodium-glucose-co-transporter-2-inhibitors/" align="left"]
